Development and validation of a quantitative polymerase chain reaction assay to evaluate minimal residual disease for T-cell acute lymphoblastic leukemia and follicular lymphoma

American Journal of Pathology

Volumn 154, Issue 4, 1999, Pages 1023-1035

  Hosler, Gregory A ^a   Bash, Robert O ^b   Bai, Xin ^a   Jain, Vinay ^c   Scheuermann, Richard H ^a,b  

^a Dept Pathol Lab of Molec Pathol ^*  (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; PRIMER DNA; PROTEIN BCL 2;

ACCURACY; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CALIBRATION; CANCER CELL; CANCER RECURRENCE; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA HYBRIDIZATION; FOLLICULAR LYMPHOMA; GENE DELETION; GENE INSERTION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; MINIMAL RESIDUAL DISEASE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SOUTHERN BLOTTING; VALIDATION PROCESS;

EID: 0032923803     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65355-2     Document Type: Article

References (64)

1. George SL, Aur RJ, Mauer AM, Simone JV: A reappraisal of the results of stopping therapy in childhood leukemia. N Engl J Med 1979, 300:269-273
2. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ, Sawitsky A, Stass S, Weinstein H, Woods WG: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990, 8:813-819
3. Wormann B: Implications of detection of minimal residual disease. Curr Opin Oncol 1993, 5:3-12
4. Shuster JJ, Falietta JM, Pullen DJ, Crist WM, Humphrey GB, Dowell BL, Wharam MD, Borowitz M: Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1990, 75:166-173
5. Pui CH: Childhood leukemias. N Engl J Med 1995, 332:1618-1630
6. Kersey JH: Fifty years of studies of the biology and therapy of childhood leukemia. Blood 1997, 90:4243-4251
7. Campana D, Pui CH: Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995, 85:1416-1434
8. Carlo-Stella C, Mangoni L, Dotti GP, Rizzoli V: Techniques for detection of minimal residual disease. Leuk Lymphoma 1995, 18:75-80
9. Drexler HG, Borkhardt A, Janssen JW: Detection of chromosomal translocations in leukemia-lymphoma cells by polymerase chain reaction. Leuk Lymphoma 1995, 19:359-380
10. Sievers EL, Loken MR: Detection of minimal residual disease in acute myelogenous leukemia. J Pediatr Hematol Oncol 1995, 17:123-133
11. van Dongen JJ, Breit TM, Adriaansen HJ, Beishuizen A, Hooijkaas H: Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia 1992, 6:47-59
12. Rabbitts TH: Chromosomal translocations in human cancer. Nature 1994, 372:143-149
13. Bash RO, Crist WM, Shuster JJ, Link MP, Amylon M, Pullen J, Carroll AJ, Buchanan GR, Smith RG, Baer R: Clinical features and outcome of T-cell acute lymphoblastic leukemia in childhood with respect to alterations at the TAL1 locus: a Pediatric Oncology Group study. Blood 1993, 81:2110-2117
14. Jonsson OG, Kitchens RL, Baer RJ, Buchanan GR, Smith RG: Rearrangements of the tal-1 locus as clonal markers for T cell acute lymphoblastic leukemia. J Clin Invest 1991, 87:2029-2035
15. Breit TM, Beishuizen A, Ludwig WD, Mol EJ, Adriaansen HJ, van Wering ER, van Dongen JJ: tal-1 deletions in T-cell acute lymphoblastic leukemia as PCR target for detection of minimal residual disease. Leukemia 1993, 7:2004-2011
16. Brown L, Cheng JT, Chen Q, Siciliano MJ, Crist W, Buchanan G, Baer R: Site-specific recombination of the tal-1 gene is a common occurrence in human T cell leukemia. Embo J 1990, 9:3343-3351
17. Aplan PD, Lombardi DP, Ginsberg AM, Cossman J, Bertness VL, Kirsch IR: Disruption of the human SCL locus by "illegitimate" V-(D)-J recombinase activity. Science 1990, 250:1426-1429
18. Bernard O, Lecointe N, Jonveaux P, Souyri M, Mauchauffe M, Berger R, Larsen CJ, Mathieu-Mahul D: Two site-specific deletions and t(1; 14) translocation restricted to human T-cell acute leukemias disrupt the 5′ part of the tal-1 gene. Oncogene 1991, 6:1477-1488
19. Yunis JJ, Oken MM, Kaplan ME, Ensrud KM, Howe RR, Theologides A: Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. N Engl J Med 1982, 307:1231-1236
20. Weiss LM, Warnke RA, Sklar J, Cleary ML: Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med 1987, 317:1185-1189
21. Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL, Korsmeyer SJ: Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985, 41:899-906
22. Tsujimoto Y, Cossrnan J, Jaffe E, Croce CM: Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985, 228:1440-1443
23. Cleary ML, Smith SD, Sklar J: Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 1986, 47:19-28
24. Cleary ML, Galili N, Sklar J: Detection of a second t(14;18) breakpoint cluster region in human follicular lymphomas. J Exp Med 1986, 164: 315-320
25. Ngan BY, Nourse J, Cleary ML: Detection of chromosomal translocation t(14;18) within the minor cluster region of bcl-2 by polymerase chain reaction and direct genomic sequencing of the enzymatically amplified DNA in follicular lymphomas. Blood 1989, 73:1759-1762
26. Lee MS, Chang KS, Cabanillas F, Freireich EJ, Trujillo JM, Stass SA: Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science 1987, 237:175-178
27. Crescenzi M, Seto M, Herzig GP, Weiss PD, Griffith RC, Korsmeyer SJ: Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease. Proc Natl Acad Sci USA 1988, 85:4869-4873
28. Baer MR: Assessment of minimal residual disease in patients with acute leukemia. Curr Opin Oncol 1998, 10:17-22
29. Lo Coco F, Diverio D, Pandolfi PP, Biondi A, Rossi V, Avvisati G, Rambaldi A, Arcese W, Petti MC, Meloni G, Mandelli F, Grignani F, Masera G, Barbui T, Pelicci PG: Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 1992, 340:1437-1438
30. Huang W, Sun GL, Li XS, Cao Q, Lu Y, Jang GS, Zhang FQ, Chai JR, Wang ZY, Waxman S, Chen Z, Chen S-J: Acute promyelocytic leukemia: clinical relevance of two major PML-RAR α isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood 1993, 82:1264-1269
31. Miller WH Jr, Levine K, DeBlasio A, Frankel SR, Dmitrovsky E, Warrell RP Jr: Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-α fusion mRNA. Blood 1993, 82:1689-1694
32. Laczika K, Mitterbauer G, Korninger L, Knobl P, Schwarzinger I, Kapiotis S, Haas OA, Kyrle PA, Pont J, Oehler L, Purtscher B, Thalhammer F, Lechner K, Jaeger U: Rapid achievement of PML-RAR α polymerase chain reaction (PCR)-negativity by combined treatment with all-trans-retinoic acid and chemotherapy in acute promyelocytic leukemia: a pilot study. Leukemia 1994, 8:1-5
33. Fukutani H, Naoe T, Ohno R, Yoshida H, Kiyoi H, Miyawaki S, Morishita H, Sano F, Kamibayashi H, Matsue K, Miyake T, Hasegawa S, Ueda Y, Kato Y, Kobayashi H, Shimazaki C, Kobayashi M, Kurane R, Sakota H, Masaki K, Wakayama T, Tohyama K, Nonaka Y, Natori H: Prognostic significance of the RT-PCR assay of PML-RARA transcripts in acute promyelocytic leukemia: The Leukemia Study Group of the Ministry of Health and Welfare (Kouseisho). Leukemia 1995, 9:588-593
34. Dibenedetto SP, Lo Nigro L, Mayer SP, Rovera G, Schiliro G: Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia. Blood 1997, 90:1226-1232
35. Gribben JG, Neuberg D, Barber M, Moore J, Pesek KW, Freedman AS, Nadler LM: Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 1994, 83:3800-3807
36. Andersen NS, Donovan JW, Borus JS, Poor CM, Neuberg D, Aster JC, Nadler LM, Freedman AS, Gribben JG: Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 1997, 90:4212-4221
37. Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF: Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med 1997, 336:317-323
38. Brisco MJ, Condon J, Hughes E, Neoh SH, Sykes PJ, Seshadri R, Toogood I, Waters K, Tauro G, Ekert H, Morley AA: Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994, 343:196-200
39. Wasserman R, Galili N, Ito Y, Silber JH, Reichard BA, Shane S, Womer RB, Lange B, Rovera G: Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. J Clin Oncol 1992, 10:1879-1888
40. Foroni L, Coyle LA, Papaioannou M, Yaxley JC, Sinclair MF, Chim JS, Cannell P, Seeker-Walker LM, Mehta AB, Prentice HG, Hoffbrand AV: Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response. Leukemia 1997, 11:1732-1741
41. Gruhn B, Hongeng S, Yi H, Hancock ML, Rubnitz JE, Neale GA, Kitchingman GR: Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome. Leukemia 1998, 12:675-681
42. Martin G, Mairs RJ: Synthesis of quantitation standards for nested competitive PCR for the determination of minimal residual disease in B-lineage acute lymphoblastic leukaemia. Leuk Res 1997, 21:807-809
43. Tobal K, Yin JA: Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8; 21). Blood 1996, 88:3704-3709
44. Nakao M, Yokota S, Horiike S, Taniwaki M, Kashima K, Sonoda Y, Koizumi S, Takaue Y, Matsushita T, Fujimoto T, Misawa S: Detection and quantification of TEL/AML1 fusion transcripts by polymerase chain reaction in childhood acute lymphoblastic leukemia. Leukemia 1996, 10:1463-1470
45. Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM: Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993, 82:1929-1936
46. Lion T: Monitoring of residual disease in chronic myelogenous leukemia: methodological approaches and clinical aspects. Leukemia 1996, 10:896-906
47. Janssen JW, Ludwig WD, Sterry W, Bartram CR: SIL-TAL1 deletion in T-cell acute lymphoblastic leukemia. Leukemia 1993, 7:1204-1210
48. Meijerink JP, Goverde GJ, Smetsers TF, Raemaekers JM, Bogman MJ, de Witte T, Mensink EJ: Quantitation of follicular non-Hodgkin's lymphoma cells carrying t(14;18) in a patient before and after allogeneic bone marrow transplantation. Ann Oncol 1994, 5:43-45
49. Gribben JG, Freedman A, Woo SD, Blake K, Shu RS, Freeman G, Longtine JA, Pinkus GS, Nadler LM: All advanced stage nonHodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991, 78:3275-3280
50. Sykes PJ, Neoh SH, Brisco MJ, Hughes E, Condon J, Morley AA: Quantitation of targets for PCR by use of limiting dilution. Biotechniques 1992, 13:444-449
51. Koch DD, Peters T Jr: Selection and evaluation methods. Textbook of Clinical Chemistry. Edited by Burtis CA, Ashwood ER. Philadelphia, WB Saunders, 1994. pp 508-525
52. Scheuermann RH, Bauer SR: Polymerase chain reaction-based mRNA quantification using an internal standard: analysis of oncogene expression. Methods Enzymol 1993, 218:446-473
53. Bai X, Hosler GA, Rogers BB, Dawson DB, Scheuermann RH: Quantitative polymerase chain reaction for human herpesvirus diagnosis and measurement of Epstein-Barr virus burden in posttransplant lymphoproliferative disorder. Clin Chem 1997, 43:1843-1849
54. Bakhshi A, Wright JJ, Graninger W, Seto M, Owens J, Cossman J, Jensen JP, Goldman P, Korsmeyer SJ: Mechanism of the t(14;18) chromosomal translocation: structural analysis of both derivative 14 and 18 reciprocal partners. Proc Natl Acad Sci USA 1987, 84:2396-2400
55. Ito Y, Miyamura K: Clinical significance of minimal residual disease in leukemia detected by polymerase chain reaction. Is molecular remission a milestone for achieving a cure? Leuk Lymphoma 1994, 16: 57-64
56. Cross NC, Hughes TP, Feng L, O'Shea P, Bungey J, Marks DI, Ferrant A, Martiat P, Goldman JM: Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. Br J Haematol 1993, 84:67-74
57. Roth MS, Antin JH, Ash R, Terry VH, Gotlieb M. Silver SM, Ginsburg D: Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood 1992, 79:276-282
58. Limpens J, Stad R, Vos C, de Vlaam C, de Jong D, van Ommen GJ, Schuuring E, Kluin PM: Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 1995, 85:2528-2536
59. Dolken G, Illerhaus G, Hirt C, Mertelsmann R: BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases. J Clin Oncol 1996, 14:1333-1344
60. Delabesse E, Bernard MC, Macintyre EA: Direct submission of tal-1 5′ breakpoint region sequence. European Molecular Biology Laboratory (EMBL) accession number Y07540, 1997
61. Lecointe N, Ferrier R, Mathieu-Mahul D: Direct submission of tal-1 d2 3′ breakpoint region sequence. European Molecular Biology Laboratory (EMBL) accession number X81027, 1994
62. Manila PS, Schugk J, Wu H, Makela O: Extensive allelic sequence variation in the J region of the human immunoglobulin heavy chain gene locus. Eur J Immunol 1995, 25:2578-2582
63. Hosler GA, Scheuermann RH: Direct submission of LQ1 internal calibration standard sequence. GenBank accession number AF116871, 1999
64. Liu J, Johnson RM, Traweek ST: Rearrangement of the BCL-2 gene in follicular lymphoma: detection by PCR in both fresh and fixed tissue samples. Diagn Mol Pathol 1993, 2:241-247